Shell is considering the sale of its US chemicals portfolio as part of a broader effort to reduce exposure to underperforming businesses and concentrate capital on higher-return activities such as oil, gas and trading.
The assets comprise four sites in Pennsylvania, Texas and Louisiana producing petrochemicals used in plastics, detergents and pharmaceuticals. They include Shell’s huge Monaca complex in Pennsylvania, which began operations in 2022 after an investment of approximately $14 billion and has capacity to produce around 1.6 million tonnes of polymers annually.
Despite substantial investment, Shell’s chemicals operations have struggled with weak margins amid global petrochemical overcapacity. The potential sale could fetch up to $8 billion — considerably below the capital Shell originally invested in the facilities.
Potential bidders reportedly include ExxonMobil, LyondellBasell, private-equity group Apollo Global Management and the chemicals arm of Kuwait Petroleum Corporation. Non-binding offers have been submitted for either individual assets or the complete portfolio.
Any transaction of this magnitude would face US regulatory review. Under the Hart-Scott-Rodino Act, large acquisitions generally require pre-merger notification and a waiting period before completion. The 2026 reporting threshold starts at $133.9 million, putting a multibillion-dollar transaction comfortably within the review framework, absent an exemption.
For an existing petrochemical producer such as ExxonMobil or LyondellBasell, regulators could scrutinise whether the acquisition substantially reduces competition in particular chemical markets. A foreign purchaser could potentially face additional national-security scrutiny.
The eventual buyer therefore matters almost as much as the price.
Source
Reuters — “Exxon, Lyondell among suitors for Shell’s US chemical assets, could fetch $8 billion, FT reports” — 24 August 2026.